Editing Neuroleptic malignant syndrome (section)

==Prognosis==
The [[prognosis]] is best when identified early and treated aggressively. In earlier studies the mortality rates of NMS ranged from 20%–38%, but by 2009 mortality rates were reported to have fallen below 10% over the previous two decades due to early recognition and improvements in management.<ref name=niraj>{{cite journal | vauthors = Ahuja N, Cole AJ |title=Hyperthermia syndromes in psychiatry |journal=Advances in Psychiatric Treatment |volume=15 |issue=3 |year=2009 |pages=181–91 |doi=10.1192/apt.bp.107.005090|doi-access=free }}</ref> Re-introduction of antipsychotics after NMS may trigger a recurrence, although in most cases it does not. With recurrence rate being 4.2% in a small, population based study.<ref name="Wijdicks 2024" /><ref name="Guinart 2021">{{cite journal |last1=Guinart |first1=Daniel |last2=Taipale |first2=Heidi |last3=Rubio |first3=Jose M |last4=Tanskanen |first4=Antti |last5=Correll |first5=Christoph U |last6=Tiihonen |first6=Jari |last7=Kane |first7=John M |title=Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort |journal=Schizophrenia Bulletin |date=21 October 2021 |volume=47 |issue=6 |pages=1621–1630 |doi=10.1093/schbul/sbab062|pmid=34013325 |pmc=8530388 }}</ref>